Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model

BACKGROUND: In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to other patients, and their daily administration was resource intensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, R., White, B., Roberts, J., Cretikos, M., Howard, M. V., Haber, P. S., Lintzeris, N., Reeves, P., Dunlop, A. J., Searles, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644557/
https://www.ncbi.nlm.nih.gov/pubmed/36348369
http://dx.doi.org/10.1186/s12913-022-08687-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644557/
https://www.ncbi.nlm.nih.gov/pubmed/36348369
http://dx.doi.org/10.1186/s12913-022-08687-8

Ejemplares similares